Filtered By:
Source: Journal of Allergy and Clinical Immunology
Condition: Chronic Obstructive Pulmonary
This page shows you your search results in order of date.
Order by Relevance | Date
Total 187 results found since Jan 2013.
E-cigarette vapour renders neutrophils dysfunctional due to filamentous actin accumulation
Electronic (e-)cigarette use continues to rise despite concerns of long-term effects, especially the risk of developing lung diseases such as chronic obstructive pulmonary disease (COPD). Neutrophils are central to the pathogenesis of COPD, with changes in phenotype and function implicated in tissue damage.
Source: Journal of Allergy and Clinical Immunology - September 4, 2023 Category: Allergy & Immunology Authors: Alice E. Jasper, Aduragbemi A. Faniyi, Lauren C. Davis, Frances S. Grudzinska, Robyn Halston, Jon Hazeldine, Dhruv Parekh, Elizabeth Sapey, David R. Thickett, Aaron Scott Source Type: research
Polygenic risk scores identify heterogeneity in asthma and chronic obstructive pulmonary disease
Asthma and chronic obstructive pulmonary disease (COPD) have distinct and overlapping genetic and clinical features.
Source: Journal of Allergy and Clinical Immunology - August 16, 2023 Category: Allergy & Immunology Authors: Matthew Moll, Joanne E. Sordillo, Auyon J. Ghosh, Lystra P. Hayden, Gregory McDermott, Michael J. McGeachie, Amber Dahlin, Anshul Tiwari, Monica G. Manmadkar, Eric D. Abston, Chandan Pavuluri, Aabida Saferali, Sofina Begum, John P. Ziniti, Amund Gulsvik, Source Type: research
News beyond our pages
Because type 2 inflammation is present in a significant proportion of patients with chronic obstructive pulmonary disease (COPD) and increases exacerbation risk, Bhatt et al (N Engl J Med 2023; https://doi.org/10.1056/NEJMoa2303951) performed a randomized, placebo-controlled phase 3 trial to investigate the efficacy of dupilumab, an mAb that inhibits the signaling of both IL-4 and IL-13 in symptomatic patients with COPD with a blood eosinophil count of at least 300 per μL. As compared to placebo, dupilumab decreased the annualized rate of exacerbations and improved lung function, quality of life, and symptom control.
Source: Journal of Allergy and Clinical Immunology - August 1, 2023 Category: Allergy & Immunology Tags: News beyond our pages Source Type: research
Causal relationship between asthma-related diseases and the risk of COVID-19: A 2-sample mendelian randomization study
We read with interest the study recently published by Skevaki et al1 in the Journal of Allergy and Clinical Immunology. Skevaki et al1 found that the differences in risk associated with coronavirus disease 2019 (COVID-19) that are observed in patients with asthma are associated with different prevalence of underlying comorbidities, particularly, chronic obstru ctive pulmonary disease (COPD). However, inconsistent associations between asthma and COVID-19 disease have been observed in epidemiology studies.
Source: Journal of Allergy and Clinical Immunology - July 10, 2023 Category: Allergy & Immunology Authors: Shu Ran, XinHong Qiu, BaoLin Liu Tags: Correspondence Source Type: research
Cystatin SN in type 2 inflammatory airway diseases
Cystatin SN, encoded by CST1, belongs to the type 2 (T2) cystatin protein superfamily. In the past decade, several publications have highlighted the association between cystatin SN and inflammatory airway diseases including chronic rhinosinusitis, rhinitis, asthma, chronic obstructive pulmonary disease, and chronic hypersensitivity pneumonitis. It is, therefore, crucial to understand the role of cystatin SN in the wider context of T2 inflammatory diseases. Here, we review the expression of cystatin SN in airway-related diseases with different endotypes.
Source: Journal of Allergy and Clinical Immunology - March 21, 2023 Category: Allergy & Immunology Authors: Bing Yan, Yimin Ren, Chang Liu, Linping Shu, Chengshuo Wang, Luo Zhang Source Type: research
Safety and tolerability of pur1800, an orally inhaled narrow spectrum kinase inhibitor, in patients with stable chronic obstructive pulmonary disease (copd).
This study evaluated the safety, tolerability and pharmacokinetics of inhaled doses of PUR1800 for 14 days in patients with stable and 1+ y ears of Grade II/III COPD.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Margaret Wasilewski, Russell Clayton, Dave Singh, Jason Perry, Aidan Curran Source Type: research
Real-world inhaler usage patterns obtained from a digital health platform
Objective data measured by digital inhalers have the potential to inform patient management. This analysis assessed real-world inhaler usage data from a Digital Health Platform (DHP) used by patients with asthma or COPD in the US.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Henry Chrystyn, Nawar Bakerly, Mark Levy, Guilherme Safioti, Sanjay Gandhi, John Logan, Bogdan Muresan Source Type: research
Cadmium Toxicity Induces Pyroptosis In Macrophages
Cadmium (Cd) toxicity contributes to chronic obstructive pulmonary disease (COPD) and other smoking-related lung disease. Caspase-1, gasdermin D (GSDMD), and gasdermin E (GSDME) are key proteins responsible for the initiation of pyroptosis. We hypothesize Cd induces host immune and inflammatory cell death in a macrophage model (RAW 264.7).
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Samuel Camilli, Carli Busler, Apoorva Desaraju, Ramani Soundararajan, Richard Lockey Source Type: research
News beyond our pages
Because of emerging evidence of early life origins of chronic obstructive pulmonary disease (COPD), there is increasing interest in investigating the prognostic value of early lung function deficits. Dharmage et al (Lancet Respir Med 2022 Oct 13; https://doi.org/10.1016/S2213-2600(22)00364-2) utilized lifetime spirometry trajectories to identify 4 distinct patterns of obstruction and restriction. Patients with a mixed pattern (with both low FEV1/FVC ratio and low FVC trajectories) had the highest risk of developing COPD, although an obstructive-only pattern (with low FEV1 trajectory) was also associated with increased risk of COPD.
Source: Journal of Allergy and Clinical Immunology - January 1, 2023 Category: Allergy & Immunology Authors: Marc E. Rothenberg, Jean Bousquet Tags: News beyond our pages Source Type: research
The gut microbiome is a significant risk factor for future chronic lung disease
This work demonstrates the link between the gut microbiome and incident respiratory diseases in a large prospective population-based cohort, suggesting the potential of the gut microbiome as a biomarker for COPD and adult-onset asthma.
Source: Journal of Allergy and Clinical Immunology - December 29, 2022 Category: Allergy & Immunology Authors: Yang Liu, Shu Mei Teo, Guillaume Meric, Howard H.F. Tang, Qiyun Zhu, Jon G. Sanders, Yoshiki Vazquez-Baeza, Karin Verspoor, Ville A. Vartiainen, Pekka Jousilahti, Leo Lahti, Teemu Niiranen, Aki S. Havulinna, Rob Knight, Veikko Salomaa, Michael Inouye Source Type: research
Airway-delivered short-chain fatty acid acetate boosts antiviral immunity during rhinovirus infection
Microbiota are recognised to play a major role in regulation of immunity through release of immunomodulatory metabolites such as short-chain fatty acids (SCFA). Rhinoviruses (RV) induce upper respiratory illnesses and precipitate exacerbations of asthma and chronic obstructive pulmonary disease through poorly understood mechanisms. Local interactions between SCFAs and antiviral immune responses in the respiratory tract have not been previously investigated.
Source: Journal of Allergy and Clinical Immunology - October 7, 2022 Category: Allergy & Immunology Authors: Krist Helen Antunes, Aran Singanayagam, Lily Williams, Tasnim Syakirah Faiez, Ana Farias, Millie M. Jackson, Fatima K. Faizi, Julia Aniscenko, Tatiana Kebadze, Punnam Chander Veerati, Lisa Wood, Nathan W. Bartlett, Ana Paula Duarte de Souza, Sebastian L. Source Type: research
Biologics for allergic and immunologic diseases
Biologics or molecularly targeted drugs are often highly effective for the treatment of allergic diseases and other immunologic disorders, and they are relatively safe for short-term use as compared with conventional approaches such as the systemic use of corticosteroids. A number of studies published in 2021 consistently demonstrated their effectiveness and also revealed unanticipated findings. Among them, clinical trials for asthma and chronic obstructive pulmonary disease using biologics targeting thymic stromal lymphopoietin, IL-33, and IL-33 receptor demonstrate d that these type 2 alarmin cytokines are also involve...
Source: Journal of Allergy and Clinical Immunology - September 1, 2022 Category: Allergy & Immunology Authors: Hideaki Morita, Kenji Matsumoto, Hirohisa Saito Tags: Review article Source Type: research
Review of biologics in allergy and immunology
Biologics or molecularly targeted drugs are often highly effective for the treatment of allergic diseases and other immunologic disorders, and they are relatively safe for short-term use as compared with conventional approaches such as the systemic use of corticosteroids. A number of studies published in 2021 consistently demonstrated their effectiveness and also revealed unanticipated findings. Among them, clinical trials for asthma and chronic obstructive pulmonary disease using biologics targeting thymic stromal lymphopoietin, IL-33, and IL-33 receptor demonstrate d that these type 2 alarmin cytokines are also involve...
Source: Journal of Allergy and Clinical Immunology - September 1, 2022 Category: Allergy & Immunology Authors: Hideaki Morita, Kenji Matsumoto, Hirohisa Saito Tags: Review article Source Type: research
Chronic rhinosinusitis is associated with non –cystic fibrosis bronchiectasis: A new clinical implication?
Bronchiectasis is a rare pulmonary disease characterized by aberrant mucociliary clearance, recurrent infections, mucus production, and mucosal damage leading to permanent dilatation of bronchi.1 Several conditions may coexist with non –cystic fibrosis bronchiectasis, such as chronic obstructive pulmonary disease (COPD), recurrent pneumonia, asthma, aspirin-exacerbated respiratory disease, allergic bronchopulmonary aspergillosis, immune deficiency, primary ciliary dyskinesia, alpha 1-antitrypsin deficiency, and obstructive sleep apnea (OSA).
Source: Journal of Allergy and Clinical Immunology - July 12, 2022 Category: Allergy & Immunology Authors: Jarkko M äntylä, Paula Kauppi, Sanna Toppila-Salmi Tags: Editorial Source Type: research
Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap
Transcriptomic analysis in a new model of asthma and chronic obstructive pulmonary disease overlap (ACO) that replicates disease features in patients, reveals novel disease mechanisms that are amenable to therapy.
Source: Journal of Allergy and Clinical Immunology - May 25, 2022 Category: Allergy & Immunology Authors: Xiaofan Tu, Richard Y. Kim, Alexandra C. Brown, Emma De Jong, Bernadette Jones-Freeman, Md Khadem Ali, Henry M. Gomez, Kurtis F. Budden, Malcolm R. Starkey, Guy J.M. Cameron, Svenja Loering, Duc H. Nguyen, Prema Mono Nair, Tatt Jhong Haw, Charlotte A. Ale Source Type: research
